plerixafor + cytarabine + daunorubicin

This is a **combination therapy** consisting of plerixafor, cytarabine, and daunorubicin primarily studied for the treatment of **acute myeloid leukemia (AML)**. **Plerixafor** is a reversible small-molecule antagonist of the CXCR4 receptor, used to disrupt interactions between leukemic blasts and the bone marrow microenvironment, thereby enhancing the effectiveness of chemotherapy[1][2][3]. **Cytarabine** is an antimetabolite chemotherapeutic agent that inhibits DNA synthesis, while **daunorubicin** is an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II, leading to DNA damage and apoptosis in malignant cells. This regimen aims to synergistically increase the susceptibility of leukemic cells to chemotherapy by mobilizing them from the protective bone marrow environment, thus improving the cytotoxic effect of cytarabine and daunorubicin[1][3]. The combination has been investigated in phase 1 trials for patients with newly diagnosed or relapsed/refractory AML, demonstrating manageable safety and some preliminary evidence of efficacy[1][3].